Schepens B - Search Results

1

Corrigendum: Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state.

Rossey I, Gilman MSA, Kabeche SC, Sedeyn K, Wrapp D, Kanekiyo M, Chen M, Mas V, Spitaels J, Melero JA, Graham BS, Schepens B, McLellan JS, Saelens X. Rossey I, et al. Among authors: schepens b. Nat Commun. 2017 Nov 29;8:16165. doi: 10.1038/ncomms16165. Nat Commun. 2017. PMID: 29184149 Free PMC article.

2

Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules.

Hultberg A, Temperton NJ, Rosseels V, Koenders M, Gonzalez-Pajuelo M, Schepens B, Ibañez LI, Vanlandschoot P, Schillemans J, Saunders M, Weiss RA, Saelens X, Melero JA, Verrips CT, Van Gucht S, de Haard HJ. Hultberg A, et al. Among authors: schepens b. PLoS One. 2011 Apr 1;6(4):e17665. doi: 10.1371/journal.pone.0017665. PLoS One. 2011. PMID: 21483777 Free PMC article.

3

Nanobodies® specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion.

Schepens B, Ibañez LI, De Baets S, Hultberg A, Bogaert P, De Bleser P, Vervalle F, Verrips T, Melero J, Vandevelde W, Vanlandschoot P, Saelens X. Schepens B, et al. J Infect Dis. 2011 Dec 1;204(11):1692-701. doi: 10.1093/infdis/jir622. Epub 2011 Oct 12. J Infect Dis. 2011. PMID: 21998474

4

Recombinant influenza virus carrying the respiratory syncytial virus (RSV) F85-93 CTL epitope reduces RSV replication in mice.

De Baets S, Schepens B, Sedeyn K, Schotsaert M, Roose K, Bogaert P, Fiers W, Saelens X. De Baets S, et al. Among authors: schepens b. J Virol. 2013 Mar;87(6):3314-23. doi: 10.1128/JVI.03019-12. Epub 2013 Jan 9. J Virol. 2013. PMID: 23302879 Free PMC article.

5

CD8+ T cell immunity against human respiratory syncytial virus.

Rossey I, Sedeyn K, De Baets S, Schepens B, Saelens X. Rossey I, et al. Among authors: schepens b. Vaccine. 2014 Oct 21;32(46):6130-7. doi: 10.1016/j.vaccine.2014.08.063. Epub 2014 Sep 16. Vaccine. 2014. PMID: 25223272 Review.

6

Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein.

Schepens B, Sedeyn K, Vande Ginste L, De Baets S, Schotsaert M, Roose K, Houspie L, Van Ranst M, Gilbert B, van Rooijen N, Fiers W, Piedra P, Saelens X. Schepens B, et al. EMBO Mol Med. 2014 Nov;6(11):1436-54. doi: 10.15252/emmm.201404005. EMBO Mol Med. 2014. PMID: 25298406 Free PMC article.

7

Small hydrophobic protein of respiratory syncytial virus as a novel vaccine antigen.

Schepens B, Schotsaert M, Saelens X. Schepens B, et al. Immunotherapy. 2015;7(3):203-6. doi: 10.2217/imt.15.11. Immunotherapy. 2015. PMID: 25804473 Free article. No abstract available.

8

IgG3 Snitcher of RSV Infections in the Very Young.

Schepens B, Saelens X. Schepens B, et al. EBioMedicine. 2017 Feb;16:10-11. doi: 10.1016/j.ebiom.2017.01.039. Epub 2017 Jan 30. EBioMedicine. 2017. PMID: 28159571 Free PMC article. No abstract available.

9

Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state.

Rossey I, Gilman MS, Kabeche SC, Sedeyn K, Wrapp D, Kanekiyo M, Chen M, Mas V, Spitaels J, Melero JA, Graham BS, Schepens B, McLellan JS, Saelens X. Rossey I, et al. Among authors: schepens b. Nat Commun. 2017 Feb 13;8:14158. doi: 10.1038/ncomms14158. Nat Commun. 2017. PMID: 28194013 Free PMC article.

10

Clinical Potential of Prefusion RSV F-specific Antibodies.

Rossey I, McLellan JS, Saelens X, Schepens B. Rossey I, et al. Among authors: schepens b. Trends Microbiol. 2018 Mar;26(3):209-219. doi: 10.1016/j.tim.2017.09.009. Epub 2017 Oct 17. Trends Microbiol. 2018. PMID: 29054341 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

101 results

Search Page